Column: Trump is on Putin's side, not America's

New Post Public Reply Private Reply Replies (0) Message Board
Bhawks
119
Quote:
Column: Trump is on Putin's side, not America's



President Donald Trump attends a joint news conference following the summit with Russian President Vladimir Putin on July 16, 2018, in Helsinki. (Brandan Smialowski/AFP)

Steve Chapman Reporter
Chicago Tribune

July 17, 2018, 4:25 PM

Once to every man and nation comes the moment to decide,

In the strife of Truth with Falsehood, for the good or evil side.

— James Russell Lowell, “The Present Crisis,” 1845

President Donald Trump faced that moment Monday in Helsinki, meeting privately for more than two hours with Russia’s Vladimir Putin and taking part in a news conference afterward. He made unmistakably clear which side he takes — and it’s not America’s.

It was a performance that was simultaneously predictable and astonishing. Anyone who has paid attention to Trump’s policies and attitude toward the Russian autocrat saw nothing more than the dismal culmination of his long pattern of accommodation and appeasement.

But it was still hard to imagine beforehand that Trump — even Trump — would conduct himself so obsequiously with Putin while blatantly defying his advisers, the U.S. intelligence community and Republicans in Congress.

Previous presidents considered pre-emptive attacks against our enemies to protect our security. This was the first pre-emptive capitulation, and it erodes our security. Given what we saw Monday, if Trump faced the prospect of impeachment, it would hardly be surprising if he sought political asylum in Russia.

On Tuesday, back in Washington, he said grudgingly that he “accepts” the conclusion of U.S. intelligence agencies that Russia interfered in the 2016 election. But it was too little, too late.

Trump is a modern version of Vidkun Quisling, the Norwegian politician who urged Adolf Hitler to invade and gained his country’s presidency during the Nazi occupation. The term “quisling” soon became a synonym for “traitor.”

But Norway was a small, weak nation confronted with a strong, aggressive one. Trump is the leader of a superpower that has been under cyberattack from a government whose military is not even close to a match for ours. He capitulated not from prudence but from preference. He has the means to oppose Putin. He lacks the will.

The most plausible explanations for his contemptible fawning on a vicious dictator and aggressor are three. The first is that Trump is a gold-plated fool — a narcissist driven by his ego and outraged by the idea that he might owe his election to Putin, who acknowledged Monday that he wanted Trump to win.

In this scenario, he is flattered by Putin’s support and naive enough to trust him. At the same time, he has to dismiss evidence that the Russians interfered, deny that he or his campaign collaborated with them, and heap contempt on Hillary Clinton.

The second possibility is that he’s a weak man who is congenitally incapable of standing up to strong ones — particularly if they share his disdain for democratic norms and the rule of law. Trump picks fights with the leaders of Western democracies such as Germany, Britain and Canada. But he loses his nerve in the presence of the likes of Putin, China’s Xi Jinping and North Korea’s Kim Jong Un.

The most disturbing option is that Trump is the conscious, faithful servant of the Kremlin, doing its bidding at whatever cost to our national interests. But why would he betray his country?

Maybe Putin has scandalous information or material that could destroy Trump’s presidency. Maybe he has bought Trump off — which could explain his refusal to release his tax returns. Maybe Trump has huge debts to Russian oligarchs and fears they will expose crimes he has committed, bankrupt him or even harm members of his family unless he does the Kremlin’s bidding.

Motives like these would explain his strange insistence on meeting with Putin one-on-one — to keep those around him from knowing the extent of his desire to please the Russians. It would account for the craven public submission to Putin at their news conference. It would explain why over and over, he diverges radically from his advisers and congressional Republicans on matters involving Russia.

But whatever Trump’s motives, he has made his choice clear. And that leaves Defense Secretary James Mattis, Director of National Intelligence Dan Coats, Secretary of State Mike Pompeo and others with the choice of doing all they can to resist the bizarre and destructive policies he is pursuing — or being shamefully complicit in them.

The same grim choice faces the GOP leadership and rank-and-file on Capitol Hill. None of them is helpless. But are they finally ready to say, “Enough”?

Trump willingly humiliated himself in Helsinki. If others in the administration and Congress choose to swallow this disgrace, they can be sure it will not be the last — and maybe not even the worst.


Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ad Council Expands Board, Taps Meta Exec as Vice Chair

Updated Category News Views 203

An Unexpected Shuffle at the Ad Council Alright, folks, let's talk shop about the recent shake-up in the nonprofit realm. The Ad Council, which has been around longer than some of the giants controlling today's marketing landscapes, just plumped up its Board of Directors with 23 new heavy-hitters. We're talking about leaders from every nook and cranny of the...

Continue Reading
Georgia-Pacific's $150M Bet on Bathroom Tissue Future

Updated Category News Views 0

Georgia-Pacific is throwing down a cool $150 million to jazz up its mill in Palatka, Florida. Yep, they're not just scrubbing the edges, but rebuilding one of the paper machines there—from the ground up. Why the fuss? Well, in the paper game, keeping your machines ahead of the pack means everything. In this case, it’s about ramping up for dear ol’ Angel Soft® bath...

Continue Reading
Nektar Therapeutics Gears Up for Q3 Financial Reveal

Updated Category News Views 56

Anticipation Builds as Nektar Preps Financial Report Ah, the life of a biotech investor, riding high or gripping the rail as tides turn with every quarterly report. This time, we're turning our gaze to Nektar Therapeutics and their Q3 financial results slated for release on November 12th, just as the market dust starts settling for the day. Now, if you’re wired to...

Continue Reading
Custom Homes Shine: Florida’s Lucrative Property Move

Updated Category News Views 0

Why Custom Homes Are Worth the Investment in Florida Ever thought about sinking some cash into Florida's real estate game? Well, building a custom home might just be your golden ticket, according to Paul H Schaefer II from Sage Homes LLC. I mean, everyone knows Florida's housing market is as spicy as a chili pepper, but custom homes seem to be the secret sauce here....

Continue Reading
Firmable Climbs G2 Ranks in Sales Intelligence

Updated Category News Views 53

Success stories aren't written overnight, and Firmable's recent leap in G2's rankings proves that point. This AI-native B2B sales powerhouse has muscled its way from #8 to #4 on the global Momentum Grid for Sales Intelligence, marking a dramatic rise that's hard to ignore. Being recognized at this level shows the company's on a solid path, but let's see what makes this...

Continue Reading
Webull Faces Class Action: Deadline Looms Dec 2026

Updated Category News Views 60

Sinking Shares: The Webull Saga Unfolds Shady business practices can really make a stock take a nosedive, and that's what's happening with Webull Corporation, trading under NASDAQ:BULL. The alarm bells started ringing when the truth about their operations and ties to China came out. Turns out, what looked like a stable American fintech platform had its roots digging deep...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 15

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
Software Updates Costly: UX Not the Biggest Culprit

Updated Category News Views 68

Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...

Continue Reading
LabWare Loop: A Game Changer for Lab Data Integrity

Updated Category News Views 58

Breaking Down Silos in Lab Environments When it comes to the controlled chaos of laboratory operations, data integrity is the name of the game. We're talking about a new way of doing things that doesn't demand a physics degree just to connect the dots between gizmos and databases. Enter LabWare Loop, a solution that's rewriting the data playbook by linking multi-vendor...

Continue Reading
SELCO and Numerica Unite: A Merger That's All Heart

Updated Category News Views 47

Big Merger in Credit Union World: SELCO and Numerica Sometimes, it ain't all about dollars and cents. That's the vibe I'm picking up from this merger of equals between SELCO Community and Numerica Credit Unions. This isn't a Wall Street hustle, it's hometown hustle—where the biggest reward isn't just a fat line at the bottom but seeing your community thrive. The Vision...

Continue Reading

Top 5 Most Recently Viewed Articles

Lucid Diagnostics Partners with LEAA Health for EsoGuard Testing

Updated Category News Views 227

Lucid Diagnostics Partners with LEAA Health for EsoGuard Testing LEAA Health's membership-based patients can now access the innovative EsoGuard esophageal precancer testing as part of their enhanced personalized care services. This collaboration marks a significant milestone for Lucid Diagnostics Inc. (Nasdaq: LUCD), a leader in cancer prevention medical diagnostics....

Continue Reading
Exploring the Growth of the Silicone Market Towards 2030

Updated Category News Views 234

Understanding the Silicone Market Dynamics The silicone market is on a significant growth trajectory, poised to reach approximately USD 33,246.3 million by 2030, with a robust compound annual growth rate (CAGR) of 5.2%. This forecast highlights the dynamics driving market expansion, making it essential for industries to adapt and embrace silicone’s diverse applications....

Continue Reading
CAPREIT Reveals Monthly Distribution for Investors

Updated Category News Views 89

CAPREIT Announces Monthly Distribution for September 2024 CAPREIT, a leading real estate investment trust in Canada, has announced a distribution of $0.125 per Unit for September 2024. This significant declaration reflects their dedication to delivering steady returns for investors. In total, this represents an annualized distribution of $1.50 per Unit. Unitholders should...

Continue Reading
Invivyd Engages Investors at Healthcare Innovation Conference

Updated Category News Views 56

Invivyd to Showcase Innovations at Healthcare Conference Invivyd, Inc. (Nasdaq: IVVD), a dedicated biopharmaceutical company focused on combating serious viral infections, has announced its participation in an upcoming prominent event, the Guggenheim Securities Healthcare Innovation Conference. This event takes place from November 11-13, offering a unique opportunity for...

Continue Reading
Athena Security Introduces Innovative Telepresence Technology

Updated Category News Views 183

Revolutionizing Security with Innovative Technologies Athena Security is making waves in the world of security technology with the introduction of its groundbreaking innovations. The newly developed Telepresence Officer stands as a significant advancement, working as a workforce multiplier. This technology is designed to meet soaring security demands in critical...

Continue Reading